Trials / Completed
CompletedNCT00402363
Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 663 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | omega-3-acid ethyl esters | |
| DRUG | Placebo |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2006-11-22
- Last updated
- 2017-01-30
- Results posted
- 2010-10-15
Locations
178 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00402363. Inclusion in this directory is not an endorsement.